Daniel Lyons, Ph.D., CFA
Daniel Lyons is a Portfolio Manager and Research Analyst on the Health Care and US Small/Mid-Cap Growth Teams at Janus Henderson Investors, a role he has held since 2018. Prior to this, he was a research analyst from 2000. He focuses on biotechnology and life science tools sectors for the Health Care Sector Research Team. Daniel started consulting for Janus in 1997 and joined the research team full time in 2000.
Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 23 years of financial industry experience.
Products Managed
Articles Written
Healthcare stocks: Positioned for a smoother ride in 2024?
Andy Acker and Dan Lyons share their outlook, saying a rapid pace of innovation and attractive valuations could propel the sector higher.
Four questions: Why invest in healthcare now?
Hear how advances in drug development, patient outcomes, and other trends are impacting the investment outlook for healthcare.
Navigating biotech’s “haves” and “have-nots”
Performance in the sector has split between companies with positive clinical data and those without.
Healthcare stocks ready for new growth
Attractive valuations and innovation are adding to the sector’s long-term appeal.
Global Perspectives: Healthcare’s underappreciated opportunities
How innovation, secular tailwinds – even regulation – are driving growth in the sector.
Hiding in plain sight: The investment case for healthcare
Why attractive valuations and new growth opportunities make healthcare worthy of another look by investors.
JH Explorer in San Diego: The future of treating diabetes
A new approach to treating diabetes could lead to weight loss and cardiovascular benefits, unlocking the potential for significant growth.
Investing through the ups and downs of biopharma research
The biopharmaceutical industry often moves to the beat of its own drummer, creating opportunities for diversification.